Journal of Oncology / 2009 / Article / Tab 7

Review Article

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Table 7

Selected clinical trials of lapatinib. MBC, metastatic breast cancer; PFS, progression free survival; OS, overall survival; TTP, time to progression.

MalignancyRegimenNumber of patientsResponse rateComments

MBCCapecitibine +/ Lapatinib [59]324 pts HER2-positive MBC that had progressed with chemotherapy (anthracycline, a taxane, and trastuzumab)Capecitabine, Lapatinib: TTP (6.2 mo) ORR (24%) Capecitabine monotherapy: TTP (4.3 mo) ORR (14%)Non-significant trend toward improved OS favoring lapatinib Fewer pts in the lapatinib arm developed brain metastases as the first site of progression (13 vs. 4%)

MBCLapatinib, Paclitaxel vs. Paclitaxel monotherapy [60]580 pts 55% received prior chemotherapy or hormonal therapy No pts received prior traztuzumabLapatinib, Paclitaxel: ORR (60%) Median TTP (8 mo) Paclitaxel monotherapy: ORR (36%) Median TTP (6 mo)Improved clinical outcome was seen with the combination without a significant change in side effect profile No difference in OS, but majority of pts were not properly tested for HER2

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.